JP2019504101A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504101A5
JP2019504101A5 JP2018540793A JP2018540793A JP2019504101A5 JP 2019504101 A5 JP2019504101 A5 JP 2019504101A5 JP 2018540793 A JP2018540793 A JP 2018540793A JP 2018540793 A JP2018540793 A JP 2018540793A JP 2019504101 A5 JP2019504101 A5 JP 2019504101A5
Authority
JP
Japan
Prior art keywords
acamprosate
piperazin
phenylsulfonyl
quinoline
baclofen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540793A
Other languages
English (en)
Japanese (ja)
Other versions
JP7027318B2 (ja
JP2019504101A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/052470 external-priority patent/WO2017134280A1/en
Publication of JP2019504101A publication Critical patent/JP2019504101A/ja
Publication of JP2019504101A5 publication Critical patent/JP2019504101A5/ja
Application granted granted Critical
Publication of JP7027318B2 publication Critical patent/JP7027318B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540793A 2016-02-05 2017-02-03 神経障害の新規の併用療法 Expired - Fee Related JP7027318B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16305128 2016-02-05
EP16305128.7 2016-02-05
EP17152720 2017-01-23
EP17152720.3 2017-01-23
PCT/EP2017/052470 WO2017134280A1 (en) 2016-02-05 2017-02-03 Novel combinatorial therapies of neurological disorders

Publications (3)

Publication Number Publication Date
JP2019504101A JP2019504101A (ja) 2019-02-14
JP2019504101A5 true JP2019504101A5 (enExample) 2020-03-12
JP7027318B2 JP7027318B2 (ja) 2022-03-01

Family

ID=58044028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540793A Expired - Fee Related JP7027318B2 (ja) 2016-02-05 2017-02-03 神経障害の新規の併用療法

Country Status (6)

Country Link
US (1) US10799499B2 (enExample)
JP (1) JP7027318B2 (enExample)
CN (1) CN109069450A (enExample)
AU (1) AU2017216288B2 (enExample)
CA (1) CA3012900A1 (enExample)
WO (1) WO2017134280A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019211135A1 (en) * 2018-01-29 2020-08-06 Pharnext Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
JP2022523919A (ja) * 2019-02-05 2022-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経変性疾患を治療するための物質および方法
CN114181201B (zh) * 2020-09-15 2023-12-01 香港科技大学 作为针对各种神经退行性疾病的潜在治疗剂的新化合物
WO2025151884A1 (en) * 2024-01-12 2025-07-17 Parsons C Lowell Use of glycosaminoglycan sulfated polysaccharides such as sodium pentosan polysulfate in combination with permeation agents to treat alzheimer's disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398108T1 (de) * 2002-03-27 2008-07-15 Glaxo Group Ltd Chinolinderivate und deren verwendung als 5-ht6 liganden
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ES2365574T3 (es) * 2007-01-11 2011-10-07 Xenoport, Inc. Formas de dosificación oral para liberación continua de un profármaco de r-baclofeno y procedimientos de tratamiento.
WO2008087123A2 (en) * 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction
ES2389958T3 (es) * 2007-03-21 2012-11-05 Glaxo Group Limited Uso de derivados de quinolina en el tratamiento del dolor
US9084742B2 (en) * 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
LT2282778T (lt) * 2008-04-29 2017-06-26 Pharnext Nauji terapijos būdai, gydant alzheimerio ligą ir susijusius sutrikimus per angiogenezės moduliaciją
UA115968C2 (uk) * 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
ES2665569T3 (es) * 2011-03-01 2018-04-26 Pharnext Tratamiento de la isquemia cerebral
EP2705843A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis

Similar Documents

Publication Publication Date Title
US10434109B2 (en) Compositions for treating neurological disorders
JP5987008B2 (ja) バクロフェンおよびアカンプロセートに基づく神経疾患の治療
JP6619744B2 (ja) 神経障害の処置のためのバクロフェン、アカンプロセート、及び中鎖トリグリセライドの併用
EA032881B1 (ru) Применение торасемида для лечения болезни альцгеймера или родственного болезни альцгеймера расстройства или травмы спинного мозга
US9931326B2 (en) Composition comprising torasemide and baclofen for treating neurological disorders
JP7027318B2 (ja) 神経障害の新規の併用療法
JP2019504101A5 (enExample)
JP7065880B2 (ja) アルツハイマー病のイダロピルジン系組合せ療法
JP6430445B2 (ja) バクロフェンおよびアカンプロセートに基づく神経疾患の治療
EP3411025A1 (en) Novel combinatorial therapies of neurological disorders
HK1233960A1 (en) Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders